iShares Neuroscience and Healthcare ETF Rating $25.08 +0.49 (+2.01%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsShort InterestBuy This Stock iShares Neuroscience and Healthcare ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IBRN Aggregate RatingModerate Buy 2.84Holdings in IBRN have an aggregate rating of Moderate Buy based on 238 analyst ratings issued in the past year covering 18 companies (61.1% of the portfolio).IBRN Aggregate Price Target$25.08High Prediction$25.08Average Prediction$25.08Low Prediction$25.08Holdings in IBRN have an aggregate price target of $25.08 and a range of $25.08 to $25.08 covering 18 companies (61.1% of the portfolio).IBRN Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy9 Buy rating(s)Moderate Buy7 Moderate Buy rating(s)Hold1 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Neuroscience and Healthcare ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 18 IBRN Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.75%ARGXargenex$708.26+0.0%3.279 of 5 stars3.10$763.47 7.8%21Trending NewsAnalyst ForecastAnalyst Revision4.41%ACADACADIA Pharmaceuticals$26.56+3.3%3.247 of 5 stars2.61$28.88 8.7%18Positive News4.39%SRRKScholar Rock$34.45+2.0%4.562 of 5 stars3.20$45.75 32.8%10Positive News4.35%SUPNSupernus Pharmaceuticals$45.06+1.7%2.2649 of 5 stars2.50$41.00 -9.0%4News CoveragePositive NewsInsider Trade4.24%NBIXNeurocrine Biosciences$138.32+1.1%4.8616 of 5 stars2.86$159.50 15.3%21News CoveragePositive News4.14%PTCTPTC Therapeutics$49.80+0.7%4.3317 of 5 stars2.63$69.15 38.9%164.09%BIIBBiogen$136.37-0.3%4.8088 of 5 stars2.34$185.74 36.2%32Positive News3.97%XENEXenon Pharmaceuticals$38.87+0.6%2.0936 of 5 stars3.00$53.20 36.9%11Positive News3.77%DNLIDenali Therapeutics$15.61+0.4%4.2909 of 5 stars3.12$33.62 115.4%17Positive News3.45%ALKSAlkermes$29.25+0.9%4.6765 of 5 stars2.83$41.08 40.5%123.38%CPRXCatalyst Pharmaceuticals$20.17+1.2%4.8906 of 5 stars3.13$33.20 64.6%8News CoveragePositive News3.03%BHVNBiohaven$15.61-0.8%3.7783 of 5 stars3.07$54.23 247.5%152.55%EWTXEdgewise Therapeutics$14.43-1.2%2.4379 of 5 stars2.91$40.55 181.0%112.28%PRAXPraxis Precision Medicines$46.93-2.0%1.6711 of 5 stars2.75$85.88 83.0%82.26%AVDLAvadel Pharmaceuticals$14.89+0.3%2.6662 of 5 stars3.14$19.67 32.1%72.14%AVXLAnavex Life Sciences$9.43-1.1%3.7305 of 5 stars3.00$44.00 366.8%2News CoverageAnalyst Forecast1.98%DYNDyne Therapeutics$13.68+2.2%3.7325 of 5 stars3.06$34.07 149.1%16Analyst Upgrade1.87%IARTIntegra LifeSciences$14.86+0.7%4.0614 of 5 stars1.78$18.63 25.3%9 This page (NYSEARCA:IBRN) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Neuroscience and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Neuroscience and Healthcare ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access